2015 - Fellow of the American Statistical Association (ASA)
Peter F. Thall spends much of his time researching Internal medicine, Surgery, Clinical trial, Chemotherapy and Gastroenterology. His Internal medicine study combines topics from a wide range of disciplines, such as Immunology and Oncology. His Oncology research includes elements of Prostate cancer, Toxicity and Docetaxel.
His Surgery research incorporates themes from Medical physics and Sarcoma. His Clinical trial study incorporates themes from Statistics, Sample size determination, Bayesian probability, Bayes' theorem and Intensive care medicine. His Chemotherapy research is multidisciplinary, relying on both Survival rate and Cancer.
Peter F. Thall mainly investigates Internal medicine, Surgery, Oncology, Clinical trial and Transplantation. As part of the same scientific family, he usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Leukemia. His work deals with themes such as Cancer, Toxicity and Urology, which intersect with Surgery.
His Oncology study deals with Prostate cancer intersecting with Docetaxel. The study incorporates disciplines such as Outcome, Bayes' theorem, Bayesian probability, Statistics and Intensive care medicine in addition to Clinical trial. He has included themes like Immunology and Fludarabine in his Transplantation study.
Internal medicine, Oncology, Bayesian probability, Clinical trial and Transplantation are his primary areas of study. His Internal medicine study frequently links to related topics such as Gastroenterology. The Oncology study combines topics in areas such as Hematopoietic stem cell transplantation, Prostate cancer and Prospective cohort study.
He has researched Bayesian probability in several fields, including Mathematical optimization and Missing data. His study in Clinical trial is interdisciplinary in nature, drawing from both Precision medicine, Bayesian hierarchical modeling, Progression-free survival and Patient subgroups. His Transplantation study combines topics from a wide range of disciplines, such as Randomized controlled trial and Acute leukemia.
His scientific interests lie mostly in Internal medicine, Oncology, Clinical trial, Randomized controlled trial and Transplantation. His multidisciplinary approach integrates Internal medicine and Gene signature in his work. His Oncology research integrates issues from Immune checkpoint, Blockade, T cell, Adverse effect and Disease.
His Clinical trial study integrates concerns from other disciplines, such as Logistic regression and Patient subgroups. He interconnects Nuclear medicine and Intensity-modulated radiation therapy in the investigation of issues within Randomized controlled trial. His Transplantation research is mostly focused on the topic Busulfan.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac.
The New England Journal of Medicine (2020)
Some covariance models for longitudinal count data with overdispersion.
Peter F. Thall;Stephen C. Vail.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang.
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva.
Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Peter F. Thall;John D. Cook.
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
E Estey;P Thall;M Andreeff;M Beran.
Journal of Clinical Oncology (1994)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio;Andrea L. Harzstark;Paul G. Corn;Sijin Wen;Sijin Wen.
Clinical Cancer Research (2013)
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Elihu H. Estey;Peter F. Thall;Sherry Pierce;Jorge Cortes.
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
Peter F. Thall;Richard M. Simon;Elihu H. Estey.
Statistics in Medicine (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: